NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

RNAC

Cartesian Therapeutics Inc

Jun 30 • 04:00PM ET

10.39

Dollar change -0.29
Percentage change -2.72	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS SRPT ARWR PBYI BLUE CRSP EDIT GILD VRTX

| Held by: VTI IWM VXF IWN IBB VTWO IWC IWO BBC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-52.64	Insider Own	67.98%	Shs Outstand	25.94M	Perf Week	5.70%
Market Cap	269.66M	Forward P/E	-	EPS next Y	-3.93	Insider Trans	1.28%	Shs Float	8.31M	Perf Month	3.90%
Enterprise Value	103.30M	PEG	-	EPS next Q	-0.82	Inst Own	20.21%	Short Float	31.62%	Perf Quarter	-28.54%
Income	-286.59M	P/S	5.63	EPS this Y	25.99%	Inst Trans	0.21%	Short Ratio	29.08	Perf Half Y	-43.75%
Sales	47.94M	P/B	-	EPS next Y	-18.32%	ROA	-102.11%	Short Interest	2.63M	Perf YTD	-41.99%
Book/sh	-0.84	P/C	1.49	EPS next 5Y	0.04%	ROE	-938.38%	52W High	29.02 -64.20%	Perf Year	-58.02%
Cash/sh	6.95	P/FCF	-	EPS past 3/5Y	12.72% 34.24%	ROIC	-	52W Low	8.46 22.81%	Perf 3Y	-75.26%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-22.95% 42.27%	Gross Margin	98.05%	Volatility	9.58% 7.74%	Perf 5Y	-88.49%
Dividend TTM	-	EV/Sales	2.15	EPS Y/Y TTM	-645.78%	Oper. Margin	-109.96%	ATR (14)	0.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.34	Sales Y/Y TTM	38.82%	Profit Margin	-597.83%	RSI (14)	49.99	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	12.34	EPS Q/Q	98.35%	SMA20	0.95%	Beta	0.36	Target Price	36.17
Payout	-	Debt/Eq	-	Sales Q/Q	-86.69%	SMA50	-1.03%	Rel Volume	0.57	Prev Close	10.68
Employees	-	LT Debt/Eq	-	Earnings	May 08 BMO	SMA200	-36.16%	Avg Volume	90.37K	Price	10.39
IPO	Jun 22, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.04% 20.00%	Trades		Volume	51,193	Change	-2.72%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Initiated	BTIG Research	Buy	$42
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform	$50
May-24-24	Initiated	Mizuho	Buy	$40
Apr-23-24	Reiterated	H.C. Wainwright	Buy	$2 → $54
Apr-23-24	Initiated	Leerink Partners	Outperform	$39
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform	$1
Jun-14-22	Reiterated	Needham	Buy	$6 → $5
Jun-06-22	Initiated	SVB Leerink	Outperform	$7
Jun-15-21	Initiated	BTIG Research	Buy	$10
Jan-26-21	Upgrade	Mizuho	Neutral → Buy	$2.50 → $8
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-20	Downgrade	Mizuho	Buy → Neutral	$2.50
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy	$8
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight	$10
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy	$33
Mar-30-17	Reiterated	UBS	Buy	$26

Show Previous Ratings

Jun-24-25 02:07PM	Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last? (Zacks) +5.39%
10:42AM	Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains? (Zacks)
10:40AM	Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? (Zacks)
07:56AM	RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains? (Zacks)
04:41AM	Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength? (Zacks)
07:05AM	Loading…
Jun-03-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-30-25 07:00AM	Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
May-13-25 07:00AM	Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-08-25 07:00AM	Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 05:35PM	Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -15.03%
May-05-25 07:48AM	Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
May-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-08-25 07:00AM	Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial (GlobeNewswire) -5.84%
Apr-02-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Apr-01-25 07:00AM	Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.24%
12:15PM	Loading…
Mar-14-25 12:15PM	Amgen data muddies outlook for Cartesian, says Oppenheimer (TipRanks)
Mar-13-25 07:00AM	Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
Feb-18-25 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-06-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jan-27-25 07:00AM	Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis (GlobeNewswire)
Jan-13-25 07:00AM	Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases (GlobeNewswire) +8.85%
Jan-07-25 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Dec-20-24 06:50AM	Cartesian Therapeutics initiated with a Buy at BTIG (TipRanks)
Dec-18-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -7.59%
Dec-04-24 06:33AM	Cartesian Therapeutics Reports Promising Phase 2b Trial Results (TipRanks) +9.56%
Dec-03-24 06:00AM	Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial (GlobeNewswire)
Nov-21-24 07:00AM	Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-24 10:01AM	Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 (GuruFocus.com)
Nov-08-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Loading…
Nov-07-24 07:00AM	Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 09:00AM	Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting (GlobeNewswire)
Oct-15-24 07:00AM	Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting (GlobeNewswire) -5.58%
Oct-04-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +7.45%
Sep-09-24 07:00AM	Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis (GlobeNewswire)
Sep-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -7.55%
Sep-03-24 07:00AM	Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) -6.02%
Aug-26-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.43%
Aug-07-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-08-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-03-24 02:25PM	Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates (Zacks) +11.73%
Jul-02-24 04:08PM	Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs (Investor's Business Daily) -35.02%
04:05PM	Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire)
06:30AM	Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Jun-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
May-23-24 12:12PM	Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 (Zacks)
May-22-24 07:00AM	Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis (GlobeNewswire)
May-13-24 04:30PM	Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) +15.38%
12:00PM	What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet (Zacks)
May-10-24 03:12PM	Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... (GuruFocus.com)
May-08-24 02:52PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 04:15PM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire) -9.85%
Apr-25-24 09:55AM	Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade (Zacks)
Apr-22-24 04:30PM	Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting (Business Wire) +12.76%
Apr-08-24 09:35AM	Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC) (Zacks)
Apr-04-24 07:30AM	Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey) -5.36% -7.55%
Mar-28-24 04:05PM	Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split (GlobeNewswire) -13.83%
Mar-14-24 09:35AM	Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-07-24 11:51PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.04%
07:00AM	Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-05-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
07:00AM	Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland (GlobeNewswire)
Feb-05-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -9.18% +5.35%
Jan-22-24 09:19AM	Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? (InvestorPlace)
Jan-08-24 07:10AM	Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity (GlobeNewswire) +5.87%
07:00AM	Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Nov-13-23 08:05AM	Selecta Biosciences Announces Merger with Cartesian Therapeutics (GlobeNewswire) -8.00%
Oct-31-23 04:03PM	Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi (GlobeNewswire) -7.20%
Aug-24-23 06:21AM	The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab (American City Business Journals)
Aug-17-23 10:20PM	Q2 2023 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics (GlobeNewswire)
Jul-14-23 07:08AM	Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26% (Simply Wall St.)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jun-03-23 08:20AM	Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five years (Simply Wall St.)
May-31-23 07:00AM	Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology (GlobeNewswire)
May-09-23 06:06AM	Newsflash: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
May-04-23 08:45AM	Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.96%
07:30AM	Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:05PM	Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update (GlobeNewswire) -5.04%
Apr-18-23 06:11AM	Investors Holding Back On Selecta Biosciences, Inc. (NASDAQ:SELB) (Simply Wall St.)
Mar-27-23 07:07AM	Is Selecta Biosciences, Inc.'s (NASDAQ:SELB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.) -5.67%
Mar-21-23 11:48AM	Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year (Benzinga)
03:30AM	Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint (GlobeNewswire)
Mar-06-23 05:59AM	Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 01:24AM	Q4 2022 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 09:25AM	Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-23 08:00AM	Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
08:00AM	Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 01:15PM	Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts (Benzinga)

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
English Emily	Chief Operations Officer	May 12 '25	Option Exercise	3.30	7,500	24,750	55,226	May 14 04:15 PM
English Emily	Chief Operations Officer	Apr 15 '25	Option Exercise	3.30	7,500	24,750	47,726	Apr 16 04:35 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	48,595	508,751	620,175	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	41,782	393,947	571,580	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	36,338	391,455	656,513	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 10 '25	Buy	10.47	8,575	89,773	8,637,273	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 09 '25	Buy	9.43	7,373	69,517	8,628,698	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Apr 11 '25	Buy	10.77	6,412	69,074	8,643,685	Apr 11 05:29 PM
SPRINGER TIMOTHY A	Director	Mar 20 '25	Buy	15.59	54,889	855,593	8,621,325	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 19 '25	Buy	14.97	20,234	302,962	8,566,436	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Mar 18 '25	Buy	14.42	14,740	212,599	8,546,202	Mar 20 07:50 PM
SPRINGER TIMOTHY A	Director	Jan 13 '25	Buy	17.35	16,945	293,958	8,527,440	Jan 15 04:08 PM
SPRINGER TIMOTHY A	Director	Jan 14 '25	Buy	18.00	4,022	72,396	8,531,462	Jan 15 04:08 PM
Jewell Christopher M	Chief Scientific Officer	Jan 10 '25	Option Exercise	3.23	9,000	29,070	62,490	Jan 13 04:09 PM
Kurtoglu Metin	Chief Technology Officer	Jan 06 '25	Sale	16.83	2,458	41,374	62,258	Jan 07 08:05 PM
Kurtoglu Metin	Chief Technology Officer	Jan 03 '25	Sale	16.72	2,417	40,417	64,716	Jan 07 08:05 PM
Miljkovic Milos	Chief Medical Officer	Jan 06 '25	Sale	16.83	948	15,957	35,393	Jan 07 08:05 PM
Miljkovic Milos	Chief Medical Officer	Jan 03 '25	Sale	16.72	932	15,585	36,341	Jan 07 08:05 PM
Jewell Christopher M	Chief Scientific Officer	Jan 06 '25	Sale	16.83	1,286	21,646	53,490	Jan 07 08:05 PM
Jewell Christopher M	Chief Scientific Officer	Jan 03 '25	Sale	16.72	1,264	21,136	54,776	Jan 07 08:05 PM
English Emily	Chief Operations Officer	Jan 06 '25	Sale	16.83	906	15,250	40,226	Jan 07 08:05 PM
English Emily	Chief Operations Officer	Jan 03 '25	Sale	16.72	891	14,899	41,132	Jan 07 08:05 PM
Brunn Carsten	President and CEO	Jan 06 '25	Sale	16.83	8,708	146,575	204,096	Jan 07 08:04 PM
Brunn Carsten	President and CEO	Jan 03 '25	Sale	16.72	8,563	143,190	212,804	Jan 07 08:04 PM
Davis Blaine	Chief Financial Officer	Jan 06 '25	Sale	16.83	4,028	67,800	94,811	Jan 07 08:04 PM
Davis Blaine	Chief Financial Officer	Jan 03 '25	Sale	16.72	3,961	66,235	98,839	Jan 07 08:04 PM
English Emily	SVP, Head of Manufacturing	Dec 26 '24	Option Exercise	3.30	7,650	25,245	25,923	Dec 30 04:11 PM
SPRINGER TIMOTHY A	Director	Dec 19 '24	Buy	17.99	25,208	453,616	8,480,914	Dec 23 05:20 PM
SPRINGER TIMOTHY A	Director	Dec 20 '24	Buy	18.94	21,800	412,968	8,502,714	Dec 23 05:20 PM
SPRINGER TIMOTHY A	Director	Dec 23 '24	Buy	19.00	5,181	98,437	8,507,895	Dec 23 05:20 PM
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Option Exercise	1.41	10,763	15,176	61,796	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Option Exercise	1.41	2,901	4,090	53,934	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Sale	25.50	10,763	274,494	51,033	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Sale	24.35	2,901	70,640	51,033	Dec 11 04:28 PM
METIN KURTOGLU	Officer	Dec 10 '24	Proposed Sale	24.35	2,901	70,640		Dec 10 04:21 PM
METIN KURTOGLU	Officer	Dec 09 '24	Proposed Sale	25.50	10,763	274,493		Dec 09 04:36 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Option Exercise	1.41	32,789	46,232	83,822	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Option Exercise	1.41	5,700	8,037	56,733	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Option Exercise	1.41	200	282	51,233	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Sale	16.67	32,789	546,560	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Sale	17.29	5,700	98,570	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Sale	19.50	200	3,900	51,033	Nov 21 06:52 PM
Jewell Christopher M	Chief Scientific Officer	Nov 20 '24	Option Exercise	3.23	14,000	45,220	39,940	Nov 21 06:50 PM
METIN KURTOGLU	Officer	Nov 21 '24	Proposed Sale	16.67	32,789	546,560		Nov 21 04:45 PM
METIN KURTOGLU	Officer	Nov 20 '24	Proposed Sale	17.29	5,700	98,570		Nov 20 04:57 PM
METIN KURTOGLU	Officer	Nov 19 '24	Proposed Sale	19.50	200	3,900		Nov 19 04:36 PM
SPRINGER TIMOTHY A	Director	Nov 15 '24	Buy	17.09	277,246	4,739,188	8,397,411	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 14 '24	Buy	16.37	96,399	1,578,156	8,120,165	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 18 '24	Buy	18.12	58,295	1,056,183	8,455,706	Nov 18 07:35 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Option Exercise	1.41	34,400	48,504	85,433	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Option Exercise	1.41	25,900	36,519	76,933	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Option Exercise	1.41	22,068	31,116	73,101	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Sale	18.39	34,400	632,641	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Sale	16.44	25,900	425,900	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Sale	17.20	22,068	379,497	51,033	Nov 18 07:32 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Option Exercise	3.23	35,000	113,050	53,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Option Exercise	3.23	20,000	64,600	38,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Sale	16.13	35,000	564,644	18,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Sale	17.14	20,000	342,888	18,273	Nov 18 07:28 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Option Exercise	3.23	36,050	116,442	61,990	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Option Exercise	3.23	16,065	51,890	42,005	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Sale	16.67	36,050	600,949	25,940	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Sale	17.06	16,065	274,093	25,940	Nov 18 07:23 PM
METIN KURTOGLU	Officer	Nov 18 '24	Proposed Sale	18.39	34,400	632,640		Nov 18 04:24 PM
METIN KURTOGLU	Officer	Nov 15 '24	Proposed Sale	17.20	22,068	379,497		Nov 15 05:07 PM
CHRISTOPHER M JEWELL	Officer	Nov 15 '24	Proposed Sale	17.06	16,065	274,093		Nov 15 04:57 PM
MILOS MILJKOVIC	Officer	Nov 15 '24	Proposed Sale	17.14	20,000	342,889		Nov 15 04:44 PM
METIN KURTOGLU	Officer	Nov 14 '24	Proposed Sale	16.44	25,900	425,900		Nov 14 05:30 PM
CHRISTOPHER M JEWELL	Officer	Nov 14 '24	Proposed Sale	16.67	36,050	600,949		Nov 14 05:29 PM
MILOS MILJKOVIC	Officer	Nov 14 '24	Proposed Sale	16.13	35,000	564,644		Nov 14 05:13 PM
SPRINGER TIMOTHY A	Director	Oct 03 '24	Buy	19.89	119,906	2,384,713	7,943,465	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 04 '24	Buy	22.58	80,301	1,813,010	8,023,766	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 02 '24	Buy	17.38	5,514	95,822	7,823,559	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Aug 12 '24	Buy	12.72	8,016	101,968	11,509	Aug 14 04:43 PM
BARABE TIMOTHY C	Director	Aug 12 '24	Buy	12.70	7,500	95,250	21,766	Aug 14 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNAC

Cartesian Therapeutics Inc

Upgrade your FINVIZ experience